European Medicines Association (EMA) statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC)
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
BSG LIVE 2025 Abstracts
Submit your abstract between 2nd December 2024 and 24th January 2025 for your chance to present your research as a poster or oral at BSG LIVE'25 in Glasgow taking place from 23rd - 26th June 2025.
Vacancy: Member of the ESE Gastroenterology & Hepatology European Specialty Examining Board
There are 2 vacancies for the examination board for the European Specialist Examination in Gastroenterology and Hepatology (ESEGH) (SCE examination as it was previously). Consultants in gastroenterology and hepatology are invited to apply to join the board.
Congratulations to our new Alcohol Lead, Prof Ewan Forrest
We are pleased to extend our congratulations to Prof Ewan Forrest who is the new BSG Alcohol Lead.